| 来源类型 | Working Paper
|
| 规范类型 | 报告
|
| DOI | 10.3386/w11223
|
| 来源ID | Working Paper 11223
|
| The Competitive Effects of Drug Withdrawals |
| John Cawley; John A. Rizzo
|
| 发表日期 | 2005-03-28
|
| 出版年 | 2005
|
| 语种 | 英语
|
| 摘要 | In September 1997, the anti-obesity drugs Pondimin and Redux, ingredients in the popular drug combination fen-phen, were withdrawn from the market for causing potentially fatal side effects. That event provides an opportunity for studying how consumers respond to drug withdrawals. In theory, remaining drugs in the therapeutic class could enjoy competitive benefits, or suffer negative spillovers, from the withdrawal of a competing drug. Our findings suggest that, while the withdrawal of a rival drug may impose negative spillovers in the form of higher patient quit rates, on the whole non-withdrawn drugs in the same therapeutic class enjoy competitive benefits in the form of higher utilization. |
| 主题 | Health, Education, and Welfare
; Health
|
| URL | https://www.nber.org/papers/w11223
|
| 来源智库 | National Bureau of Economic Research (United States)
|
| 引用统计 |
|
| 资源类型 | 智库出版物
|
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/568860
|
推荐引用方式
GB/T 7714 |
John Cawley,John A. Rizzo. The Competitive Effects of Drug Withdrawals. 2005.
|
|
文件名：
|
w11223.pdf
|
|
格式：
|
Adobe PDF
|
此文件暂不支持浏览
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
